9th October 2010 - New research


Movement Disorders [2010] Oct 5 (W.G.Ondo, L.Shinawi, S. Moore) Complete abstract

Parcopa is an orally disintegrating combination of L-dopa and carbidopa for use in the treatment of Parkinson's Disease. L-dopa and carbidopa is the same combination that is in Sinemet. However, unlike Sinemet, Parcopa rapidly disintegrates on the tongue and does not require water for dissolving or swallowing it. For more information go to Parcopa. Because Parcopa disintegrates in the mouth, it was suggested that there is the potential for it to shorten the time taken from its consumption until the ridding or reduction of Parkinson's Disease symptoms. This would make Parcopa advantageous over the use of Sinemet. However, when compared to the use of Sinemet, there were no significant differences in any of the means of assessment, including changes in symptoms, adverse events, or drug preference. It did not even make any difference to the time taken for the drug to start having effect, which is the primary reason for its proposed use. However, according to the authors "all trends did favor" Parcopa, suggesting a slight benefit. For more current news go to Parkinson's Disease News.


E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports





2006-2010  Viartis
2015-11-06 08:55:42
[email protected]